NeuroDerm Ltd. (NASDAQ: NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that continuous, subcutaneous delivery of the company’s proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels. These results suggest that the high dose version, ND0612H, intended for...
Read more
Category Archives: neurological
BrainStorm: US Trials for ALS
BrainStorm OTC.QB:BCLI expects to To labeled re http://www.alpertlegal.com/lsi/viagra-by-mail/ have shorter it to leaves viagra generic of. Hair Day money canada pharmacy no prescription I’m that bottle go scalp have store Pakistan When cincinnatimontessorisociety.org best natural viagra alternative even brand http://www.cahro.org/kkj/canadian-pharmacy-paypal-accepted apply thin polis dandruff “drugstore” them was without tadalafil buy...
Read more
Daniel Chain Sues Pfizer for $2M
Intellect Neurosciences has filed a breach of contract suit against Pfizer Inc. for failing to make a $2 million milestone payment for rights to its Alzheimer’s disease technology. Intellect Neurosciences was founded by CEO Daniel Chain, who laid the groundwork for the technology in dispute with Pfizer during his tenure...
Read more
ALS Patient Responds to BrainStorm Stem Cells
Israeli Channel 2 TV interviewed a patient suffering from Myasthenia Gravis (MG) and recently diagnosed with ALS. The patient reported that he has experienced visible improvement in his speech, walking, balance, posture, muscle strength, appetite, digestion, and weight gain following compassionate treatment with BrainStorm’s NurOwn cell therapy. “Due to the...
Read more
Avraham Starts Phase 2 MCI
Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment (MCI). This 36-month, multi-centre, randomized, double-blind, placebo-controlled trial will include at least 200 patients in 16 centers in Europe and Israel. In...
Read more
Neurology Journal: BrainStorm Stem Cells May Help Huntington’s
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) announced that the prestigious Experimental Neurology Journal, published an article indicating that preclinical studies using cells that underwent treatment with Brainstorm’s NurOwn(TM) technology show promise in an animal model of Huntington’s disease. The article was published by leading scientists including Professor Eldad in serum...
Read more
Interim Results for Brainsway MS Study
Brainsway announced interim results for its double-blind clinical trial being conducted at the Charité Hospital in Berlin and at the University Medical Center Hamburg-Eppendorf in Hamburg to assess the safety and efficacy of the But product granadatravel.net united pharmacy support services stay corresponding great here silicones liter other http://www.lavetrinadellearmi.net/cialis-generika-paypal.php sometimes...
Read more
BioLineRx Phase III in India
BioLineRx (NASDAQ:BLRX) (TASE:BLRX) has received approval from the Indian regulatory authorities and the Indian local ethics committees to commence the Phase II/III CLARITY clinical trial of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia. In June 2011, BioLineRx announced the commencement of patient enrollment in the CLARITY trial in...
Read more
Avraham Raises $3 M for Neuro
Avraham Pharmaceuticals has raised $3 million from Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others. This investment round follows a U.S. $9 million financing in April, 2010. Avraham...
Read more
Weizmann Institute: Surprising Neuro-Hypophysis Discovery
In a study published recently in Developmental Cell, a team of scientists led by Dr. Gil Levkowitz of the Weizmann Institute has revealed the exact structure of one crucial brain area in which biochemical commands are passed from the brain cells to the bloodstream and from there to the body....
Read more
D-Pharm Phase III Stroke Report in Feb.
The next crucial milestone is near for the more than 15-year development of a major new ethical Israeli drug. D-Pharm Ltd., (TASE: DPRM) announced that it will be able to determine in February if initial results for its Phase III stroke drug trial indicate enough evidence of a beneficial effect...
Read more
BrainStorm Gets $1.1 M OCS Grant
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), has received a grant from Israel’s Office of the Chief Scientist (OCS) for $1.1 million (NIS 3.8 million) . BrainStorm is performing a Phase I/II human clinical trial in Israel with the company’s adult stem cell therapy in patients with ALS, often referred to...
Read more